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In 2005, the International Committee of Medical Journal Editors (ICMJE) initiated a 
policy requiring investigators to deposit information about trial design into an 
accepted clinical trials registry before the onset of patient enrolment.1  
This policy aimed to ensure that information about the existence and design of 
clinically directive trials was publicly available, an ideal that leaders in evidence-
based medicine have advocated for decades.2  
The policy precipitated much angst among research investigators and sponsors, who 
feared that registration would be burdensome and would stifle competition. Yet, the 
response to this policy has been overwhelming. The ICMJE promised to reevaluate 
the policy in 2 years after implementation.  
Here, we summarize that reevaluation, specifically commenting on registries that 
meet the policy requirements, the types of studies that require registration, and the 
registration of trial results. As is always the case, the ICMJE establishes policy only 
for the 12 member journals (a detailed description of the ICMJE and its purpose is 
available at www.icmje.org), but many other journals have adopted our initial trial 
registration recommendations, and we hope that they will also adopt the modifications 
discussed in this update. 
The research community has embraced trial registration. Before the ICMJE policy, 
ClinicalTrials.gov, the largest trial registry at the time, contained 13[THSP]153 trials; 
this number climbed to 22[THSP]714 one month after the policy went into effect.3 In 
April 2007, the registry contained over 40[THSP]000 trials, with more than 200 new 
trial registrations occurring weekly (Zarin D. Personal communication). The 4 other 
registries that meet the ICMJE criteria have also grown as scores of journals have 
adopted the ICMJE clinical trials registration policy.  
In response to burgeoning registration, many investigators, sponsors, and government 
agencies have asked the ICMJE to recognize their local registries as databases that 
meet the policy. Fortunately, the World Health Organization’s (WHO) International 
Clinical Trial Registry Platform (ICTRP), which was nascent when the ICMJE began 
to require trial registration, has matured rapidly and provides options for those that 
desire a wider array of registries.  
The ICTRP has taken the first steps toward developing a network of primary and 
partner registers that meet WHO-specified criteria.4 Primary registers are WHO-
selected registers managed by not-for-profit entities that will accept registrations for 
any interventional trials, delete duplicate entries from their own register, and provide 
data directly to the WHO. Partner registers, which will be more numerous, will 
include registers that submit data to primary registers but limit their own register to 
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trials in a restricted area (such as a specific disease, company, academic institution, or 
geographic region). 
The ICMJE strongly supports the WHO’s efforts, through the ICTRP, to develop a 
coordinated process for identifying, gathering, deduplicating, and searching trials 
from registries around the world, thus eventually providing a 1-stop search portal for 
those seeking information about clinical trials. In addition to the 5 existing registries, 
the ICMJE will now also accept registration in any of the primary registers that 
participate in the WHO ICTRP. Because it is critical that trial registries are 
independent of for-profit interests, the ICMJE policy requires registration in a WHO 
primary register rather than solely in a partner register, since for-profit entities 
manage some partner registers. As previously, trial registration with missing or 
uninformative fields for the minimum data elements is inadequate.1 
Initially, the ICMJE required registration of all clinically directive trials, which it 
defined as “any research project that prospectively assigns human subjects to 
intervention or comparison groups to study the cause-and-effect relationship between 
a medical intervention and a health outcome”.1 In May 2005, the ICMJE clarified this 
definition to exclude preliminary trials designed to study pharmacokinetics or major 
unknown toxicity (phase I trials).5 However, the ICMJE recognizes the potential 
benefit of having information about preliminary trials in the public domain, because 
these studies can guide future research or signal safety concerns.  
Consequently, the ICMJE is expanding the definition of the types of trials that must 
be registered to include these preliminary trials and adopts the WHO’s definition of 
clinical trial: ““any research study that prospectively assigns human participants or 
groups of humans to one or more health-related interventions to evaluate the effects 
on health outcomes”.4 Health-related interventions include any intervention used to 
modify a biomedical or health-related outcome (for example, drugs, surgical 
procedures, devices, behavioural treatments, dietary interventions, and process-of-
care changes). Health outcomes include any biomedical or health-related measures 
obtained in patients or participants, including pharmacokinetic measures and adverse 
events. As previously, purely observational studies (those in which the assignment of 
the medical intervention is not at the discretion of the investigator) will not require 
registration.  
The ICMJE member journals will start to implement the expanded definition of 
clinically directive trials for all trials that begin enrolment on or after 1 July 2008. 
Those who are uncertain whether their trial meets the expanded ICMJE definition 
should err on the side of registration if they wish to seek publication in an ICMJE 
journal. 
Over the time during which registration of trial methods has become common 
practice, several forces have begun advocating for registration of trial results. We 
recognize that the climate for results registration will probably change dramatically 
and unpredictably over coming years. For the present, the ICMJE will not consider 
results posted in the same primary clinical trials register in which the initial 
registration resides as previous publications if the results are presented in the form of 
a brief, structured (<500 words) abstract or table.  
The ICMJE favours a standard abstract format for results reporting, and the 
CONSORT (Consolidated Standards for the Reporting of Trials) group’s forthcoming 
  
NZMJ 15 June 2007, Vol 120 No 1256 Page 3 of 4 
URL: http://www.nzma.org.nz/journal/120-1256/2586/ © NZMA 
 
guidelines for abstracts related to trials may be one such option. The ICMJE believes 
that parties interested in results registration should consider requiring the deposition 
of such an abstract in the registry 24 months after closure of data collection if results 
are not published in a peer-reviewed venue by that time. The registered abstract 
should either cite any related full, peer-reviewed publications or include a statement 
that indicates that the report has not yet been published in a peer-reviewed journal.  
Researchers should be aware that editors may consider more detailed deposition of 
trial results in publicly available registries to be prior publication. When submitting a 
paper, authors should fully disclose to editors all posting in registries of results of the 
same or closely related work. 
Three years ago, trials registration was the exception; now it is the rule. Registration 
facilitates the dissemination of information among clinicians, researchers, and 
patients, and it helps to assure trial participants that the information that accrues as a 
result of their altruism will become part of the public record. The WHO’s global 
efforts towards comprehensive trials registration and the ICMJE’s requirements for 
registration aim to increase public trust in medical science. 
Key summary points: 
• In addition to accepting registration in any of the 5 existing registries, the 
ICMJE will accept registration of clinical trials in any of the primary registers 
that participate in the WHO ICTRP. Registration in a partner register only is 
insufficient. 
• The ICMJE will begin to implement the WHO definition of clinical trials for 
all trials that begin enrolment on or after 1 July 2008. This definition states 
that a clinical trial is “any research study that prospectively assigns human 
participants or groups of humans to one or more health-related interventions to 
evaluate the effects on health outcomes.” 
• The ICMJE will not consider results posted in the same clinical trials registry 
in which the primary registration resides to be previous publication if the 
results are presented in the form of a brief, structured (<500 words) abstract or 
table. 
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